Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

246 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII.
Crivellari D, Bonetti M, Castiglione-Gertsch M, Gelber RD, Rudenstam CM, Thürlimann B, Price KN, Coates AS, Hürny C, Bernhard J, Lindtner J, Collins J, Senn HJ, Cavalli F, Forbes J, Gudgeon A, Simoncini E, Cortes-Funes H, Veronesi A, Fey M, Goldhirsch A. Crivellari D, et al. J Clin Oncol. 2000 Apr;18(7):1412-22. doi: 10.1200/JCO.2000.18.7.1412. J Clin Oncol. 2000. PMID: 10735888 Clinical Trial.
First-line fadrozole HCI (CGS 16949A) versus tamoxifen in postmenopausal women with advanced breast cancer. Prospective randomised trial of the Swiss Group for Clinical Cancer Research SAKK 20/88.
Thürlimann B, Beretta K, Bacchi M, Castiglione-Gertsch M, Goldhirsch A, Jungi WF, Cavalli F, Senn HJ, Fey M, Löhnert T. Thürlimann B, et al. Ann Oncol. 1996 Jul;7(5):471-9. doi: 10.1093/oxfordjournals.annonc.a010635. Ann Oncol. 1996. PMID: 8839901 Free article. Clinical Trial.
Identifying breast cancer patients at high risk for bone metastases.
Colleoni M, O'Neill A, Goldhirsch A, Gelber RD, Bonetti M, Thürlimann B, Price KN, Castiglione-Gertsch M, Coates AS, Lindtner J, Collins J, Senn HJ, Cavalli F, Forbes J, Gudgeon A, Simoncini E, Cortes-Funes H, Veronesi A, Fey M, Rudenstam CM. Colleoni M, et al. J Clin Oncol. 2000 Dec 1;18(23):3925-35. doi: 10.1200/JCO.2000.18.23.3925. J Clin Oncol. 2000. PMID: 11099322
Influence of endocrine-related factors on response to perioperative chemotherapy for patients with node-negative breast cancer.
Colleoni M, Gelber S, Coates AS, Castiglione-Gertsch M, Gelber RD, Price K, Rudenstam CM, Lindtner J, Collins J, Thürlimann B, Holmberg SB, Cortes-Funes H, Simoncini E, Murray E, Fey M, Goldhirsch A; International Breast Cancer Study Group. Colleoni M, et al. J Clin Oncol. 2001 Nov 1;19(21):4141-9. doi: 10.1200/JCO.2001.19.21.4141. J Clin Oncol. 2001. PMID: 11689582 Clinical Trial.
Risk factors for locoregional recurrence among breast cancer patients: results from International Breast Cancer Study Group Trials I through VII.
Wallgren A, Bonetti M, Gelber RD, Goldhirsch A, Castiglione-Gertsch M, Holmberg SB, Lindtner J, Thürlimann B, Fey M, Werner ID, Forbes JF, Price K, Coates AS, Collins J; International Breast Cancer Study Group Trials I through VII. Wallgren A, et al. J Clin Oncol. 2003 Apr 1;21(7):1205-13. doi: 10.1200/JCO.2003.03.130. J Clin Oncol. 2003. PMID: 12663706 Clinical Trial.
[Therapeutic milestones in tumor therapy].
Fey MF. Fey MF. Ther Umsch. 1999 Dec;56(12):726-9. doi: 10.1024/0040-5930.56.12.726. Ther Umsch. 1999. PMID: 10638280 Review. German.
246 results